Premaitha Health PLC (LON:NIPT)‘s stock had its “corporate” rating restated by analysts at FinnCap in a report issued on Tuesday. They currently have a GBX 20 ($0.25) price target on the stock. FinnCap’s target price suggests a potential upside of 138.80% from the company’s current price.

Shares of Premaitha Health PLC (LON:NIPT) opened at 8.082 on Tuesday. Premaitha Health PLC has a 12-month low of GBX 6.50 and a 12-month high of GBX 21.50. The stock’s market capitalization is GBX 18.44 million. The stock has a 50 day moving average of GBX 9.03 and a 200 day moving average of GBX 9.40.

TRADEMARK VIOLATION NOTICE: This piece was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this piece can be accessed at

Premaitha Health PLC Company Profile

Premaitha Health PLC, formerly ViaLogy plc, is engaged in molecular diagnostics business for research, and the development and commercialization of gene analysis techniques. The Company’s techniques are used for pre-natal screening (NIPT) and other clinical applications in the early detection, monitoring and treatment of disease.

Receive News & Stock Ratings for Premaitha Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Premaitha Health PLC and related stocks with our FREE daily email newsletter.